글로벌 연구동향
핵의학
- 2024년 04월호
[Clin Immunol .] Autoimmune and auto-inflammatory adverse events after COVID-19 vaccination in the United States건양대 / 김성장, 심성렬*
- 출처
- Clin Immunol .
- 등재일
- 2024 Feb:259:109882. doi: 10.1016/j.clim.2023.1098
- 저널이슈번호
- 내용
Abstract
We identified 3620 autoimmune-related adverse events among 223.2 million US residents using Vaccine Adverse Events Reporting System and the COVID-19 Data Tracker. This study is the first to quantify the cumulative incidence of autoimmune and auto-inflammatory adverse events after COVID-19 vaccination. We reported autoimmune and auto-inflammatory adverse events across 6 major classes of medical conditions and stratified by age, sex, and manufacturer.Affiliations
Seong-Jang Kim 1, Taeho Greg Rhee 2, Sung Ryul Shim 3
1Department of Nuclear Medicine, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea; Department of Nuclear Medicine, College of Medicine, Pusan National University, Yangsan, Republic of Korea; BioMedical Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea.
2Department of Psychiatry, School of Medicine, Yale University, New Haven, CT, USA; VA New England Mental Illness, Research, Education and Clinical Center (MIRECC), VA Connecticut Healthcare System, West Haven, CT, USA; Department of Public Health Sciences, School of Medicine, University of Connecticut, Farmington, CT, USA.
3Department of Biomedical Informatics, College of Medicine, Konyang University, 158 Gwanjeodong-ro, Seo-gu, Daejeon 35365, Republic of Korea; Konyang Medical data Research group-KYMERA, Konyang University Hospital, Daejeon, Republic of Korea. Electronic address: sungryul.shim@gmail.com.
- 키워드
- Adverse event; Autoimmune disease; COVID-19; Vaccination.
- 덧글달기
- 이전글 [J Nanobiotechnology .] Development of finely tuned liposome nanoplatform for macrophage depletion
- 다음글 [Korean J Radiol .] Dosimetric Analysis of a Phase I Study of PSMA-Targeting Radiopharmaceutical Therapy With [177Lu]Ludotadipep in Patients With Metastatic Castration-Resistant Prostate Cancer